Peripheral sympatholytic actions of four AT1 antagonists: Are they relevant for long-term antihypertensive efficacy?

Journal of Hypertension

Volumn 23, Issue 10, 2005, Pages 1861-1867

  Dendorfer, Andreas ^a   Dominiak, Peter ^a   Tempel, Klaus ^a   Raasch, Walter ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

AT1 receptor antagonists; Catecholamines; Pithed rats; Sympathetic system

Indexed keywords

ANGIOTENSIN II; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; NORADRENALIN;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTROSTIMULATION; HYPERTENSION; LONG TERM CARE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STIMULUS RESPONSE; SYSTOLIC BLOOD PRESSURE;

EID: 29344438069     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000179510.86265.63     Document Type: Article

References (42)

1. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262:E763-E778.
2. Starke K. Action of angiotensin on uptake, release and metabolism of 14C-noradrenaline by isolated rabbit hearts. Eur J Pharmacol 1971; 15:112-123.
3. Dendorfer A, Thornagel A, Raasch W, Grisk O, Tempel K, Dominiak P. Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension 2002; 40:348-354.
4. Li Q, Dale WE, Hasser EM, Blaine EH. Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency. Am J Physiol 1996; 271:R200-R207.
5. Henegar JR, Brower GL, Kabour A, Janicki JS. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol 1995; 269:H1564-H1569.
6. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Jensen G, Friberg P. Differentiated response of the sympathetic nervous system to angiotensin-converting enzyme inhibition in hypertension. Hypertension 2000; 36:543-548.
7. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet 1979; 1:1213-1215.
8. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454-2458.
9. De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 2003; 146:E17.
10. Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 1993; 22:699-704.
11. Dendorfer A, Raasch W, Tempel K, Dominiak P. Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat. J Hypertens 2002; 20:1151-1156.
12. Guimaraes S, Pinheiro H, Tavares P, Loio A, Moura D. Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol 2001; 363:509-514.
13. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril. J Hypertens 2001; 19:465-473.
14. Wong PC, Bernard R, Timmermans PB. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension 1992; 19:663-667.
15. Qiu HY, Henrion D, Levy BI. Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats. Hypertension 1994; 24:317-321.
16. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats. Fundament Clin Pharmacol 2003; 17:83-91.
17. Raasch W, Dominiak P, Ziegler A, Dendorfer A. Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension 2004; 44:346-351.
18. Ohbayashi Y, Tsutamoto T, Sakaguchi T, Tanaka T, Kanamori T, Yokohama H, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003; 42(Suppl. 1):S71-S74.
19. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21:1761-1769.
20. Struck J, Muck P, Trübger D, Handrock R, Weidinger G, Dendorfer A, Dodt C. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 2002; 20:1143-1149.
21. Teruya H, Muratani H, Takishita S, Sesoko S, Matayoshi R, Fukiyama K. Brain angiotensin II contributes to the development of hypertension in Dahl-Iwai salt-sensitive rats. J Hypertens 1995; 13:883-890.
22. Leenen FH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 2001; 37:981-984.
23. Bunting MW, Widdop RE. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats. Br J Pharmacol 1995; 116:3181-3190.
24. Kawano Y, Yoshida K, Matsuoka H, Omae T. Chronic effects of central and systemic administration of losartan on blood pressure and baroreceptor reflex in spontaneously hypertensive rats. Am J Hypertens 1994; 7:536-542.
25. DePasquale MJ, Fossa AA, Holt WF, Mangiapane ML. Central DuP 753 does not lower blood pressure in spontaneously hypertensive rats. Hypertension 1992; 19:668-671.
26. Berecek KH, Robertson JD, Thorstad MH. Central administration of a specific angiotensin II receptor antagonist on baroreflex function in spontaneously hypertensive rats. J Hypertens 1991; 9: 365-371.
27. Atkinson J, Sonnay M, Sautel M, Fouda AK. Chronic treatment of the spontaneously hypertensive rat with captopril attenuates responses to noradrenaline in vivo but not in vitro. Naunyn Schmiedebergs Arch Pharmacol 1987; 335:624-628.
28. Raasch W, Bartels T, Schwartz C, Häuser W, Rütten H, Dominiak P. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors? J Hypertens 2002; 20:2495-2504.
29. Gillespie JS, Muir TC. A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. Br J Pharmacol Chemother 1967; 30:78-87.
30. Häuser W, Dendorfer A, Nguyen T, Dominiak P. Effects of the AT1 antagonist HR 720 in comparison to losartan on stimulated sympathetic outflow, blood pressure, and heart rate in pithed spontaneously hypertensive rats. Kidney Blood Press Res 1998; 21:29-35.
31. Kaufman LJ, Vollmer RR. Endogenous angiotensin II facilitates sympathetically mediated hemodynamic responses in pithed rats. J Pharmacol Exp Ther 1985; 235:128-134.
32. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 2001; 19:2241-2250.
33. Dominiak P, Elfrath A, Türck D. Biosynthesis of catecholamines and sympathetic outflow in spontaneously hypertensive rats (SHR) after chronic treatment with CE blocking agents. J Cardiovasc Pharmacol 1987; 10(Suppl. 7):S122-S124.
34. Stegbauer J, Oberhauser V, Vonend O, Rump LC. Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats. Cardiovasc Res 2004; 61:352-359.
35. El Muayed M, Stegbauer J, Oberhauser V, Vonend O, Rump LC. AT1 and AT2-receptor antagonists inhibit Ang II-mediated facilitation of noradrenaline release in human atria. J Cardiovasc Pharmacol 2004; 43:318-324.
36. Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:244-251.
37. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA. Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan. Eur J Pharmacol 2003; 469:117-124.
38. Moreau N, Richer C, Vincent MP, Giudicelli JF. Interaction between SR 47436, a new angiotensin II antagonist and sympathetic nervous system in pithed SHR rats. Arch Mal Coeur Vaiss 1993; 86:1269-1274.
39. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266:114-120.
40. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260:175-181.
41. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319:137-146.
42. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25:14-21.